ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase

June 18, 1993

FDA Approves Xeloda For Breast Cancer Treatment.

September 28, 2001

NIH Tells Grant Applicants One Resubmission Is Enough.

October 24, 2008

Source Identified for Hepatitis A Contamination of LAK-IL-2 Trials; Six MIs Seen; Rosenberg Updates Intramural Results

October 24, 1986

ONS Award Winners, Grantees, Announced At Annual Congress

July 27, 1990

NCI Considers Making Prevention Trial From NSABP; Other Groups Approached

May 13, 1994